Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

7 evidence topics · 4 sources

Atomoxetine label: pharmacokinetic parameters by CYP2D6 metabolizer type
ParameterOther CYP2D6 metabolizer typesCYP2D6 poor metabolizers
Accumulation“1.1-fold”“3.3-fold”
Absolute bioavailability“63%”“94%”
Median time to maximum concentration“1 hour”“2.5 hour”
Atomoxetine half-life“5.2 hours”“21.6 hours”
Atomoxetine apparent oral clearance“0.35 L/hr/kg”“0.03 L/hr/kg”
Primary metabolic pathways“CYP2D6”“Other CYP enzymes”
Oxybutynin label: R-oxybutynin and S-oxybutynin after a single 10 mg extended-release dose
ParameterR-oxybutyninS-oxybutynin
Cmax (ng/mL), mean (SD)“1.0 (0.6)”“1.8 (1.0)”
Tmax (h), mean (SD)“12.7 (5.4)”“11.8 (5.3)”
Half-life (h), mean (SD)“13.2 (6.2)”“12.4 (6.1)”
AUCinf (ng•h/mL), mean (SD)“21.3 (12.2)”“39.5 (21.2)”